|
A Prospective Observational Study to Compare the Effects of Methyldopa and Labetalol in Pregnancy Induced Hypertension
|
|
| Author:
|
HETA SHAH, RK GOYAL, GM VYAS, DR SHAH, BA VYAS
|
| Abstract:
|
Pregnancy induced hypertension (PIH) is an important cause of maternal-perinatal morbidity
as well as mortality. Despite the availability of a range of antihypertensive medicines,
unavoidable adverse outcomes are observed. The aim of the study was to monitor the effects
of alpha methyl dopa and labetalol and its feto-maternal outcomes in pregnancy.
This prospective observational study was carried out in a tertiary hospital and Maternity
home in Bardoli, Gujarat. Pregnant womens’ demographic particulars, obstetric history,
medication details and treatment outcomes were gathered from following up of patients.
Study describes the average dose of methyldopa and labetalol required to control BP to be
1026.3± 366.63 mg and 164.3± 48.79 mg respectively in a single drug therapy plan and 950±
34.30 mg and 200 mg in a combination therapy group respectively. In both, alpha
methyldopa and labetalol group, the average gestational age for development of PIH was 31
weeks. There was no statistical difference in the age of patients among different treatment
arms. In all treatment groups, majority of the pregnant women were primi gravida. In
combination therapy group high rate of preterm delivery (20%) as well as C-section delivery
(86.7%) was observed. Simultaneously minimum baby weight (0.5 kg) was also found to be
in combination therapy group.
Methyldopa was the most commonly prescribed antihypertensive drug. Labetalol is a more
potent drug to achieve adequate control of blood pressure. Despite utilization of standard
antihypertensive drugs high rates of caesarean section and IUGR conclude that conventional
antihypertensive treatment is a controller rather than preventer.
|
| Keyword:
|
PIH, Bardoli, methyl dopa, labetalol, feto-maternal outcomes
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|